Diosmin -isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use

Natural Product Communications

Volumn 8, Issue 4, 2013, Pages 545-550

  Bogucka Kockaa, Anna ^a   Wozniaka, Michal ^a   Feldob, Marcin ^a   Kockic, Janusz ^a   Szewczyk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Diosmin; Hemorrhagic disorders; Pharmaceutical formulations; Plant material; Vein wall remodeling; Venous stasis

Indexed keywords

BAROSMA BETULINA EXTRACT; CITRUS LATIFOLIA EXTRACT; CITRUS RETICULATA EXTRACT; CITRUS SINENSIS EXTRACT; DAFLON; DIOSED; DIOSMIN; DIOVEN; FLAVONOID; HYSSOPUS OFFICINALIS EXTRACT; PLACEBO; PLANT EXTRACT; UNCLASSIFIED DRUG;

BAROSMA BETULINA; BLEEDING; BODY FLUID; CITRUS; CITRUS LATIFOLIA; DRUG ACTIVITY; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG USE; HUMAN; HYSSOPUS OFFICINALIS; NONHUMAN; REVIEW; TABLET FORMULATION; VEIN DISEASE; VEIN INSUFFICIENCY; VENOUS STASIS;

CHEMISTRY, PHARMACEUTICAL; DIOSMIN; PLANT EXTRACTS;

EID: 84876245725     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. El-Shafae AM, El-Domiaty MM. (2001) Improved LC methods for the determination of diosmin and/or hesperidin in plant extracts and pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis, 26, 539-545;.
2. Londoño-Londoño J, Rodrigues de Lima V, Lara O, Gil A, Crecsynski Pasa TB, Arango GJ, Pineda JRR. (2010) Clean recovery of antioxidant flavonoids from citrus peel: Optimizing an aqueous ultrasound-assisted extraction method. Food Chemistry, 119, 81-87;.
3. Saeidi I, Hadjmohammadi MR, Peyrovi M, Iranshahi M, Barfi B, Babaei AB, Dust AM. (2011) HPLC determination of hesperidin, diosmin and eriocitrin in Iranian lime juice using polyamide as an adsorbent for solid phase extraction. Journal of Pharmaceutical and Biomedical Analysis, 56, 419-422;.
4. Kanaze FI, Bounartzi MI, Niopas I. (2004) A validated HPLC determination of the flavone aglycone diosmetin in human plasma. Biomedical Chromatography, 18, 800-804;.
5. Kanaze FI, Gabrieli C, Kokkalou E, Georgarakis M, Niopas I. (2003) Simultaneous reversed-phase high-performance liquid chromatographic method for the determination of diosmin, hesperidin and naringin in different citrus fruit juices and pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis, 33, 243-249;.
6. Campanero MA, Escolar M, Perez G, Garcia-Quetglas E, Sadaba B, Azanza JR. (2010) Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 51, 875-881;.
7. Janeczko Z, Hubicka U, Krzek J, Podolak I. (2003) Qualitative and quantitative analysis of diosmin in tablets by thin-layer chromatography with densitometric UV detection. Journal of Planar Chromatography, 16, 377-380;.
8. Shawky E. (2012) Development and validation of an HPTLC method for the simultaneous determination of diosmin and hesperidin in different citrus fruit extracts and pharmaceutical formulations. Journal of Planar Chromatography - Modern TLC, 25/2, 138-144;.
9. Dugo P, Presti ML, Ohman M, Fazio A, Dugo G, Mondello L. (2005) Detemination of flavonoids in citrus fruits juices by micro-HPLC-ESI/Ms. Journal of Separation Science, 28, 1149-1156;.
10. Spanakis M, Kasmas S, Niopas I. (2009) Simultaneous determination of the flavonoid aglycones diosmetin and hesperetin in human plasma and urine by a validated GC/MS method: in vivo metabolic reduction of diosmetin to hesperetin. Biomedical Chromatography, 23, 124-131.
11. Batchvarov IV, Batselova MG, Damyanov II. (2010) One-year diosmin therapy (600 mg) in patiens with chronic venous insufficiency - results and analysis. Journal of Biomedical and Clinical Research, 3/1, 51-54;.
12. Boccalon H, Salvadori C, Benedittini D, Steru D, Vilain C. (1996) Therapeutic equivalence of two dosage forms of a micronized flavonoid fraction in patients with chronic venous insufficiency. Current Therapeutic Research, 57, 757-766.
13. Lyseng-Williamson KA, Perry CM. (2003) Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs, 63, 71-100;.
14. Shoab SS, Scurr JH, Coleridge-Smith PD. (1999) Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. European Journal of Vasccular and Endovascular Surgery, 18/4, 334-338;.
15. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. (2006) Chronic venous disease. The New England Journal of Medicine, 355, 488-498;.
16. Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. (2000) Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. Journal of Vascular Surgery, 31/3, 456-461.
17. Monographs. (2004) Diosmin. Alternative Medicine Review, 9/3, 308-311.
18. Ivashev MN, Andreeva OA, Bandyukova VA, Dragaleva TD. (1995) Isolation of diosmin from plants of the genus Vicia and Hyssopus officinalis and its influence on blood coagulation. Pharmaceutical Chemistry Journal, 29/10, 707-709.
19. Silambarasan T, Raja B. (2012) Diosmin, a bioflavonoid reverses alterations in blood pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt induced hypertensive rats. European Journal of Pharmacology, 679, 81-89.
20. Dholakiya SL, Benzeroual KE. (2011) Protective effect of diosmin on LPS-induced apoptosis in PC12 cells and inhibition of TNF-a expression. Toxicology in Vitro, 25, 1039-1044.
21. Srinivasan S, Pari L. (2012) Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats. Chemico-Biological Interactions, 195/1, 43-51.
22. Glinski W, Chodynicka B, Roszkiewicz J, Bogdanowski T, Lacewicz-Toruń B, Kaszuba A, Bowszyc J, Nowak A, Wnorowski J, Wšsik F, Glińska- Ferenz M, Błaszczyk M, Strzyga P, Pachocki R. (1999) The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicenter, controlled, randomized study. Phlebology, 14, 151-157.
23. Cova D, De Angelis L, Giavarini F, Palladini G, Perego R. (1992) Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology, 30, 29-33.
24. European Pharmacopoeia 5.0 (2005) Monographs D-E. Diosmin. Council of Europe, Strasbourg, 1452-1453.
25. Moldovan Z, Aboul-Enein HY. (2011) A sensitive spectrophotometric method for determination of diosmin using sodium nitroprusside as a chromogenic reagent. Instrumentation Science and Technology, 39/2, 135-148;
26. Bunaciu AA, Udristioiu GE, Ruta LL, Fleschin S, Aboul-Enein HY. (2009) Determination of diosmin in pharmaceutical formulations using Fourier transform infrared spectrophotometry. Saudi Pharmaceutical Journal, 17, 303-306;.
27. Moldovan Z, Bunaciu AA, Al-Omar MA, Aboul-Enein HY. (2010) A spectrophotometric method for diosmin determination. The Open Chemical and Biomedical Methods Journal, 3, 123-127.
28. El-Shahawi MS, Bashammakh AS, El-Mogy T. (2006) Determination of trace levels of diosmin in a pharmaceutical preparation by adsorptive stripping voltammetry at a glassy carbon electrode. Analytical Sciences, 22, 1351-1354;.
29. Hanuštiak P, Mikelová R, Potéšil D, Hodek P, Siborovà M, Kizek R. (2005) Electrochemical behaviour of flavonoids on a surface of a carbon paste electrode. Biomedical Papers (Supplement 1), 149, 44-47;.
30. Adam V, Mikelova R, Hubalek J, Hanustiak P, Beklova M, Hodek P, Horna A, Trnkova L, Stiborova M, Zeman L, Kizek R. (2007) Utilizing of square wave voltammetry to detect flavonoids in the presence of human urine. Sensors, 7, 2402-2418.
31. Tsymonianis EC, Floras G, Antoniou N, Papanikolaou N, Siakas R Tassis A. (1996) Low- molecular-weight heparins and Daflon for prevention of postoperative thrombo- embolism. World Journal of Surgery, 20, 968-972;.
32. Labrid C. (1987) Proprietes pharmacologiques de Daflon 500 mg. Journal of Internal Medicine, 85 (suppl), 30-36;.
33. Tsouderos Y. (1992) Efficacy of Daflon 500 mg in the treatment of chronic venous insufficiency. Phlebology, 7 (suppl 2), 45-52;.
34. Laurent R, Gilly R, Frileux C. (1988) Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. International Angiology: a Journal of the International Union of Angiology, 7 (suppl 2), 39-43;.
35. Duhault J, Pillon G. (1992) Mecanisme d'action de Daflon 500 mg sur le tonus veineux noradrenergique. Arteres Veines, 11, 217-218;.
36. Gargouil YM. (1989) Effects of Daflon 500 mg on bovine vessel contractility. International Journal of Angiology, 8 (suppl 4), 19-22;.
37. Cotonat A. (1989) Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lumph duct. International Journal of Angiology, 8 (suppl 4), 15-18;.
38. Bouskela E, Donyo KA, Verbeuren TJ. (1995) Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. International Journal of Microcirculation: Clinical and Experimental, 15 (Suppl. 1), 22-26;.
39. Pascarella L, Lulic D, Penn AH, Alsaigh T, Lee J, Shin H, Kapur V, Bergan JJ, Schmid-Schönbein GW. (2008) Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. European Journal of Vascular and Endovascular Surgery, 35/1, 102-110;.
40. Boisneau-Geniaux D. (1988) Activite thérepeutique de Daflon 500 mg sur les troubles trophiques de l'insuffisance veineuse. Angiologie, 5 (suppl 73), 20-23;.
41. Lacombe C, Bucherer C, Lelevrie JC. (1988) Hemorheological improvement after Daflon 500 mg treatment in diabetes. International Angiology, 7 (suppl 2), 21-24;.
42. Stueker O. (1989) Daflon 500 mg depresses bradykinin-ischemia-induced microvascular leakage of FITC Dextran in rat cremaster muscle. International Angiology, 8 (suppl 4), 39-44;.
43. McHale NG, Hollywood MA. (1994) Control of lymphatic pumping: interest of Daflon 500 mg. Phlebology, (suppl 1), 23-25;.
44. Blume J, Langehbahn H, de Champvallins M. (1992) Quantification of edema using the volumeter technique: therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology, 7 (suppl 2), 37-40;.
45. Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, Van Landuyt H, Gillet-Terver MN, Guillot B, Levesque H, Miqnot J, Pillion G, Février B, Dubeaux D. (1997) Efficacy of Daflon 500 mg in venous leg ulcer healing: A double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology, 48/1, 77-85.
46. Bujan J, Jimenez-Cossio JA, Jurado F, Gimeno MJ, Pascual G, Garcia-Honduvilla N, Dominguez B, Bellon JM. (2000) Evaluation of the smooth muscle cell component and apoptosis in the varicose vein wall. Histology and Histopathology, 15, 745-752;.
47. Kowalewski R, Głowiński S, Sobolewski K, Wolańska M, Płoński A. (2000) Przebudowa macierzy miedzykomórkowej w scianie zylaków. Polski Przeglad Chirurgiczny (in Polish), 72, 912-920;.
48. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, Jacob MP. (2001) Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. The Journal of Pathology, 193/3, 398-407;.
49. Kowalewski R, Malkowski A, Sobolewski K, Gacko M. (2009) Evaluation of aFGF/bFGF and FGF signaling pathway in the wall of varicose veins. Journal of Surgical Research, 155/1, 165-172.
50. Narayana KR, Reddy MS, Chaluvadi MR, Krishna DR. (2001) Bioflavonoids classification, oharmacological, biochemical effects and therapeutic potential. Indian Journal of Pharmacology, 33, 2-16;.
51. Herrera MD, Zarzuelo A, Jiménez J, Marhuenda E, Duarte J. (1996) Effects of flavonoids on rat aortic smooth muscle contractility: structure - activity relationships. General Pharmacology, 27/2, 273-277.
52. Pascarella L, Schmid-Schönbein GW, Bergan J. (2005) An animal model of venous hypertension: the role of inflammation in venous valve failure. Journal of Vascular Surgery, 41/2, 303-311.
53. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. (2000) The inflammatory reaction during venous hypertension in the rat. Microcirculation, 7/1, 41-52.
54. Cyrino FZ, Bottino DA, Lerond L, Bouskela E. (2004) Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch. Clinical and Experimental Pharmacology & Physiology, 31/3, 159-162.
55. Miao H, Hu YL, Shiu YT, Yuan S, Zhao Y, Kaunas R, Wang Y, Jin G, Usami S, Chien S. (2005) Effects of flow patterns on the localization and expression of VE- cadherin at vascular endothelial cell junctions: in vivo and in vitro investigations. Journal of Vascular Research, 42/1, 77-89.
56. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbore Jr MA. (2001) Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proceedings of the National Academy of Sciences USA, 98/8, 4478-4485.